Next Article in Journal
Contingency Management for Treatment of Cannabis Use Disorder in Co-Occurring Mental Health Disorders: A Systematic Review
Previous Article in Journal
Psychometric Properties of the Italian Version of the Embodied Sense-of-Self Scale
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Brain Sciences
Volume 13
Issue 1
10.3390/brainsci13010033
Review Report
brainsci-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Case Report
Peer-Review Record

Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma

Brain Sci. 2023, 13(1), 33; https://doi.org/10.3390/brainsci13010033
by Yu-Ju Tseng 1, Chun-Nan Chen 2, Ruey-Long Hong 3, Woon-Man Kung 4,5 and Abel Po-Hao Huang 6,*
Reviewer 1:
Ramy Abdelnaby
Brain Sci. 2023, 13(1), 33; https://doi.org/10.3390/brainsci13010033
Submission received: 9 November 2022 / Revised: 15 December 2022 / Accepted: 20 December 2022 / Published: 23 December 2022
(This article belongs to the Topic Advances in Neurocritical Care)

Round 1

Reviewer 1 Report

I have read the manuscript (Posterior Reversible Encephalopathy Syndrome After Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma) very carefully. The authors present a neurooncological complicated with PRES after Lenvatinib Therapy. It is a well written manuscript with helpful figures. The topic is relevant, interesting, and original. The main question is to present a case with a rare complication of a Therapy with Lenvatinib in a patient with an Olfactory Neuroblastoma. Compared with other published material, it presents the current state of the case + the not well known complication. 

I still have some comments though.

It's discussion may need argumentation if the hypertension per se could be the cause of PRES and not the medication itself, even if it is already mentioned in the drug information. And it still need more differential diagnosis from a neurological point of view.  

Otherwise I wonder why there is no Neurologist or Neurosurgeon involved in the case presentation.

Author Response

Dear Reviewer, thank you for your valuable suggestions, please see the attachment for our responds.

Author Response File: Author Response.docx

Reviewer 2 Report

1. Please, improve the abstract description. Remember that in most indexations, only the abstract is provided. E.g., provide more specific information.

2. Please provide a table with all the cases already reported with PRES and lenvatinib.

3. Could the authors explain why they believed that PRES was associated with lenvatinib if the same drug was used for about five months before the presentation?

It is difficult to associate a causative drug when the patient uses many other drugs.

It is advised to calculate the Naranjo algorithm, including the result in the report.

4. It is advised to provide a figure about the proposed mechanism.

Author Response

Dear Reviewer, thank you for your valuable suggestions, please see the attachment for our responds.

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

Thank you for the response. I dont have further commments. 

Reviewer 2 Report

Satisfactory

Back to TopTop